Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 22, 2026 is 2.23. In the previous year, Financial Leverage (Equity Multiplier) was 2.27 — a change of -1.53% (lower).

Financial Leverage

2.23

YoY

-1.53%

Last updated:

Financial Leverage (Equity Multiplier) of Tibet Duo Rui Pharmaceutical Co is 2025 2.23 . Financial Leverage (Equity Multiplier) of Tibet Duo Rui Pharmaceutical Co was 2024 2.27 . It decreases by -1.53% lower compared to the previous year.

The Tibet Duo Rui Pharmaceutical Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
3.16 CNY
Jan 1, 2019
1.96 CNY
Jan 1, 2020
1.54 CNY
Jan 1, 2021
1.07 CNY
Jan 1, 2022
1.20 CNY
Jan 1, 2023
1.39 CNY
Jan 1, 2024
2.27 CNY
Jan 1, 2025
2.23 CNY
The Tibet Duo Rui Pharmaceutical Co Financial Leverage history
YEARFinancial LeverageYoY
2.23-1.53%
2.27+63.32%
1.39+16.12%
1.20+11.39%
1.07-30.22%
1.54-21.36%
1.96-38.13%
3.16—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

Financial Leverage (Equity Multiplier) of Tibet Duo Rui Pharmaceutical Co is 2.23 in 2025.

Financial Leverage (Equity Multiplier) of Tibet Duo Rui Pharmaceutical Co changed from 2.27 to 2.23, representing a -1.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Tibet Duo Rui Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Tibet Duo Rui Pharmaceutical Co

All Key Metrics — Tibet Duo Rui Pharmaceutical Co